Assessment of the Therapeutic Effects of Steroid, Ketorolac, and Normal Saline in the Management of Lateral Epicondylitis

Evaluation of the Effect of Methylprednisolone, Ketorolac, and Normal Saline in the Treatment of Lateral Epicondylitis: A Randomized Clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250729066680N1

Enrollment

Registered

2025-11-15

Start date

2025-09-23

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lateral Epicondylitis. Lateral epicondylitis

Interventions

Intervention 1: Intervention group: A: One cubic centimeter of the study drug, methylprednisolone, is drawn into a sterile syringe. The patient lies on the bed with the elbow flexed and the hand place

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with lateral epicondylitis. Symptom duration ranging from one to six months

Exclusion criteria

Exclusion criteria: Patients with systemic inflammatory diseases Known hypersensitivity or allergy to the medications used Medial epicondylitis on the same side Carpal tunnel syndrome on the same side Pregnancy and breastfeeding Having diabetes History of elbow fracture or acute injury Coagulation disorders or use of anticoagulant medications Patients with psychological disorders Having a cardiac pacemaker

Design outcomes

Primary

Measure	Time frame
Evaluation of the Effect of Methylprednisolone, in the Treatment of Lateral Epicondylitis. Timepoint: At baseline and at 2, 6, and 12 weeks post-study initiation. Method of measurement: The study questionnaire included the VAS (Visual Analog Scale) ? PRTEE (Patient-Rated Tennis Elbow Evaluation) ? QuickDASH (The shortened version of the Disabilities of the Arm, Shoulder,and Hand questionnaire).;Evaluation of the Effect of Ketorolac in the Treatment of Lateral Epicondylitis. Timepoint: At baseline and at 2, 6, and 12 weeks post-study initiation. Method of measurement: The study questionnaire included the VAS (Visual Analog Scale) ? PRTEE (Patient-Rated Tennis Elbow Evaluation) ? QuickDASH (The shortened version of the Disabilities of the Arm, Shoulder,and Hand questionnaire).;Evaluation of the Effect of Normal Saline in the Treatment of Lateral Epicondylitis. Timepoint: At baseline and at 2, 6, and 12 weeks post-study initiation. Method of measurement: The study questionnaire included the VAS (Visual Analog Scale) ? PRTEE (Patient-Rated Tennis Elbow Evaluation) ? QuickDASH (The shortened version of the Disabilities of the Arm, Shoulder,and Hand questionnaire).	—

Measure

Time frame

Evaluation of the Effect of Methylprednisolone, in the Treatment of Lateral Epicondylitis. Timepoint: At baseline and at 2, 6, and 12 weeks post-study initiation. Method of measurement: The study questionnaire included the VAS (Visual Analog Scale) ? PRTEE (Patient-Rated Tennis Elbow Evaluation) ? QuickDASH (The shortened version of the Disabilities of the Arm, Shoulder,and Hand questionnaire).;Evaluation of the Effect of Ketorolac in the Treatment of Lateral Epicondylitis. Timepoint: At baseline and at 2, 6, and 12 weeks post-study initiation. Method of measurement: The study questionnaire included the VAS (Visual Analog Scale) ? PRTEE (Patient-Rated Tennis Elbow Evaluation) ? QuickDASH (The shortened version of the Disabilities of the Arm, Shoulder,and Hand questionnaire).;Evaluation of the Effect of Normal Saline in the Treatment of Lateral Epicondylitis. Timepoint: At baseline and at 2, 6, and 12 weeks post-study initiation. Method of measurement: The study questionnaire included the VAS (Visual Analog Scale) ? PRTEE (Patient-Rated Tennis Elbow Evaluation) ? QuickDASH (The shortened version of the Disabilities of the Arm, Shoulder,and Hand questionnaire).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmirhosseinJamali

Iran University of Medical Sciences

dr.amirhosseinjamali@gmail.com+98 21 6435 2368

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026